DE69926407D1 - Behandlung von krebs mit tetraethylthiuramdisulfid - Google Patents

Behandlung von krebs mit tetraethylthiuramdisulfid

Info

Publication number
DE69926407D1
DE69926407D1 DE69926407T DE69926407T DE69926407D1 DE 69926407 D1 DE69926407 D1 DE 69926407D1 DE 69926407 T DE69926407 T DE 69926407T DE 69926407 T DE69926407 T DE 69926407T DE 69926407 D1 DE69926407 D1 DE 69926407D1
Authority
DE
Germany
Prior art keywords
cancer
tetraethylthiuramdisulfide
treatment
tetraethylthiuram disulfide
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926407T
Other languages
English (en)
Other versions
DE69926407T2 (de
Inventor
Preston Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charlotte Mecklenburg Hospital
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of DE69926407D1 publication Critical patent/DE69926407D1/de
Application granted granted Critical
Publication of DE69926407T2 publication Critical patent/DE69926407T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/03—Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
    • C12Y116/03001—Ferroxidase (1.16.3.1), i.e. ceruloplasmin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
DE69926407T 1999-09-08 1999-11-15 Behandlung von krebs mit tetraethylthiuramdisulfid Expired - Lifetime DE69926407T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/392,122 US6589987B2 (en) 1998-09-08 1999-09-08 Method of treating cancer using tetraethyl thiuram disulfide
US392122 1999-09-08
PCT/US1999/027193 WO2001017522A1 (en) 1999-09-08 1999-11-15 Method of treating cancer using tetraethyl thiuram disulfide

Publications (2)

Publication Number Publication Date
DE69926407D1 true DE69926407D1 (de) 2005-09-01
DE69926407T2 DE69926407T2 (de) 2006-05-24

Family

ID=23549328

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926407T Expired - Lifetime DE69926407T2 (de) 1999-09-08 1999-11-15 Behandlung von krebs mit tetraethylthiuramdisulfid

Country Status (9)

Country Link
US (1) US6589987B2 (de)
EP (1) EP1214063B1 (de)
JP (1) JP2003514769A (de)
AT (1) ATE300291T1 (de)
AU (1) AU782029B2 (de)
CA (1) CA2384059C (de)
DE (1) DE69926407T2 (de)
ES (1) ES2244237T3 (de)
WO (1) WO2001017522A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US20120030779A1 (en) 2007-01-18 2012-02-02 University Of Utah Research Foundtion Compositions and methods for detecting, treating, or preventing reductive stress
CN102026625A (zh) * 2008-03-17 2011-04-20 犹他州大学研究基金会 二硫代氨基甲酸金属螯合物及其制备和应用的方法
GB201020860D0 (en) * 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
EP3311843A1 (de) * 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Zusammensetzungen enthaltend dithiocarbamat und cyclodextrin
WO2018081309A1 (en) 2016-10-26 2018-05-03 Cantex Pharmaceuticals, Inc. Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
DK3459526T3 (da) * 2017-09-26 2021-05-25 Palacky Univ In Olomouc Biotilgængelige dithiocarbamat-metalkompleks-nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf
KR20190056758A (ko) 2017-11-17 2019-05-27 주식회사 지뉴브 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법
EP3693740A1 (de) * 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verbesserte dithiocarmabatbasierende verbindungen, therapien und diagnostik
CN111135175B (zh) * 2020-01-17 2022-09-16 中国医学科学院放射医学研究所 Dsf-2在制备抗肿瘤和抗辐射药物中的应用
WO2021257880A1 (en) * 2020-06-18 2021-12-23 Spring Discovery, Inc. Use of aldh modulators or gasdermin d inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system
US11351128B1 (en) * 2021-05-13 2022-06-07 Lance L. Gooberman Pharmaceutical compositions and methods of administration
CN114010624B (zh) * 2021-12-13 2023-03-28 上海纳米技术及应用国家工程研究中心有限公司 双硫仑和甲氨蝶呤在制备抗肝癌药物中的应用
WO2024046332A1 (zh) * 2022-08-29 2024-03-07 石贵中 医药组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
US4426372A (en) 1980-08-08 1984-01-17 Regents Of The University Of Minnesota Inhibition of undesired effects of platinum(II) compounds
US4594238A (en) 1980-08-08 1986-06-10 Regents Of University Of Minnesota Inhibition of undesired effect of platinum compounds
US4581224A (en) 1980-08-08 1986-04-08 Regents Of The University Of Minnesota Inhibition of undesired effect of platinum compounds
US4762705A (en) 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4645661A (en) 1984-06-29 1987-02-24 St. Jude Children's Research Hospital Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same
US5187193A (en) 1988-09-12 1993-02-16 University Of Rochester Method for stimulating transplanted bone marrow cells
US5035878A (en) 1988-09-12 1991-07-30 University Of Rochester Use of dithiocarbamates to counteract myelosuppression
JPH04202139A (ja) 1990-11-30 1992-07-22 Tosoh Corp 血管新生抑制剤
JP3426599B2 (ja) 1991-11-08 2003-07-14 ヘモゾル インコーポレイテッド 薬物担体としてのヘモグロビン
US5380747A (en) 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5783596A (en) 1992-10-30 1998-07-21 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5792787A (en) 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
CA2269838A1 (en) 1996-11-06 1998-05-14 Morris D. Faiman Method for treatment of glutamate related disorders
IL122892A0 (en) 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
IL122891A0 (en) 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate

Also Published As

Publication number Publication date
WO2001017522A1 (en) 2001-03-15
CA2384059C (en) 2010-06-22
US6589987B2 (en) 2003-07-08
EP1214063A1 (de) 2002-06-19
AU2025500A (en) 2001-04-10
JP2003514769A (ja) 2003-04-22
US20030065026A1 (en) 2003-04-03
DE69926407T2 (de) 2006-05-24
CA2384059A1 (en) 2001-03-15
ES2244237T3 (es) 2005-12-01
ATE300291T1 (de) 2005-08-15
AU782029B2 (en) 2005-06-30
EP1214063B1 (de) 2005-07-27

Similar Documents

Publication Publication Date Title
DE69926407D1 (de) Behandlung von krebs mit tetraethylthiuramdisulfid
DE60136730D1 (de) Methode zur behandlung von krebs mit dithiocarbamat-derivaten
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
MY140767A (en) Compounds, methods and compositions
ATE363850T1 (de) Elektronenquelle für gerät zum behandeln von lebensmitteln und verfahren
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
HRP20050436A2 (en) Quinolinyl-pyrrolopyrazoles
TW200510927A (en) Stimulus-sensitive composition, compound and pattern formation method using the stimulation-sensitive composition
DE60319066D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
GEP20084539B (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
NO20050640L (no) Rutenium anticancer komplekser
NZ331327A (en) Serine protease inhibitors having an acylguanidine side chain
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
WO2003075828A3 (en) Compounds useful in the treatment of cancer
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
NO952781L (no) Potensiering av temozolomid i humane tumorceller
HK1033910A1 (en) Use of erythropoietin in the treatment of multiple myeloma
IL151692A0 (en) Polyamine analogues as cytotoxic agents
EP1359909A4 (de) Krebstherapie unter verwendung von triptolid-prodrugs
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
WO2003073857A3 (de) Biologisch aktive kupferorganische mittel
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition